Development
Lantern Pharma Inc.
LTRN
$3.32
-$0.11-3.21%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.25M | 6.38M | 6.16M | 5.83M | 5.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.83M | 15.45M | 14.65M | 14.43M | 13.12M |
| Operating Income | -16.83M | -15.45M | -14.65M | -14.43M | -13.12M |
| Income Before Tax | -15.16M | -14.26M | -14.01M | -14.26M | -14.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.16 | -14.26 | -14.01 | -14.26 | -14.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.16M | -14.26M | -14.01M | -14.26M | -14.42M |
| EBIT | -16.83M | -15.45M | -14.65M | -14.43M | -13.12M |
| EBITDA | -16.81M | -15.44M | -14.64M | -14.42M | -13.11M |
| EPS Basic | -1.40 | -1.31 | -1.29 | -1.31 | -1.32 |
| Normalized Basic EPS | -0.87 | -0.82 | -0.81 | -0.82 | -0.78 |
| EPS Diluted | -1.40 | -1.31 | -1.29 | -1.32 | -1.32 |
| Normalized Diluted EPS | -0.87 | -0.82 | -0.81 | -0.82 | -0.78 |
| Average Basic Shares Outstanding | 43.43M | 43.41M | 43.38M | 43.40M | 43.71M |
| Average Diluted Shares Outstanding | 43.43M | 43.41M | 43.38M | 43.40M | 43.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |